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A B S T R A C T
Purpose
To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A,
MAGE-3, and survivin in patients with melanoma with distant metastasis.
Patients and Methods
We examined 84 patients with follow-up after analysis (cohort A), 18 long-term survivors with an
extraordinarily favorable course of disease before analysis ( 24 months survival after first
occurrence of distant metastases; cohort B), and 14 healthy controls. Circulating antigen-reactive
T cells were characterized by intracellular cytokine staining after in vitro stimulation.
Results
In cohort A patients, the presence of T cells responding to peptides from NY-ESO-1, Melan-A, or
MAGE-3 and the M category according to the American Joint Committee on Cancer classification
were significantly associated with survival. T cells responding to NY-ESO-1 and Melan-A (hazard
ratios, 0.29 and 0.18, respectively) remained independent prognostic factors in Cox regression
analysis and were superior to the M category in predicting outcome. Median survival of patients
possessing T cells responding to NY-ESO-1, Melan-A, or both was 21 months, compared with 6
months for all others. NY-ESO-1–responsive T cells were detected in 70% of cohort A patients
surviving  18 months and in 50% of cohort B patients. Melan-A responses were found in 42%
and 47% of patients in cohorts A and B, respectively. In contrast, the proportion was only 22% for
NY-ESO-1 and 23% for Melan-A in those who died within 6 months.
Conclusion
The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent
prognostic impact on survival in advanced melanoma. Our findings support the therapeutic
relevance of Melan-A and NY-ESO-1 as targets for immunotherapy.
J Clin Oncol 30:1835-1841. © 2012 by American Society of Clinical Oncology
INTRODUCTION
The prognosis of patients with melanoma with unre-
sectable distant metastasis is poor, with amedian sur-
vivalof9monthsand5-year survivalof less than20%.1
Lactate dehydrogenase (LDH) is the only well-
accepted serumbiomarker inmalignantmelanoma. It
has been part of the American Joint Committee on
Cancer (AJCC) staging systemsince 2001.2-4Other se-
rummarkersofmelanomacellorigin(eg,S100b,MIA)
have been investigated, but none are as yet widely ac-
cepted.5,6Currentperipheral bloodbiomarkersdonot
allowtheidentificationofeitherpatientswiththeworst
prognosis or patientswhomay survive longer term.
In contrast to factors related to or derived from
the melanoma cell itself, immune-related biomark-
ers have rarely been described. Long-term survival
even in advanced diseasewas observed in a subset of
patients after treatment with interleukin-2 (IL-2)7
or ipilimumab.8 Those agents are believed to act
indirectly through the immune system. Immune
system–based prognostic markers might therefore
be useful in tumor-free patients to indicate the like-
lihood of long-term survival and may serve as pre-
dictive markers for response to immunotherapies.
Thus far, interferon alfa (IFN-) –induced au-
toantibodies and pretherapeutic serum cytokine
profiles have been described to predict outcome af-
ter treatment with IFN-.9,10 C-reactive protein,
IL-6, and IL-10 concentrations in serum have like-
wise been reported to serve as prognostic markers,
but their specificity seems limited.11-14 The humoral
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immune response against TA90 has been found to be prognostically
relevant in patients receiving an allogeneic melanoma vaccine.15,16
Whether the frequency of circulating regulatory T cells, natural killer
cells,myeloid-derived suppressor cells, or others does haveprognostic
impact has only been analyzed in small cohorts of patients with mel-
anoma, with equivocal results.17-20
Specific immunotherapy of solid tumors mainly aims to induce
or increase the number of T cells directed against epitopes of tumor
antigens; it has been under intense investigation. Although a high
frequency of circulating antigen–specific T cells after vaccination has
been reported in many trials, correlations with clinical outcome have
beennotoriously inconclusive.21-23On theotherhand, adirect impact
of these types of cells has been demonstrated by impressive clinical
responses in up to 70%of patients withmelanoma on adoptive trans-
fer of tumor-infiltrating lymphocytes or T-cell receptor–transduced
lymphocytes.24,25 T cells specific for melanoma-associated antigens
have also been detected in the peripheral blood of patients with mel-
anoma without vaccination or other immunotherapies.26,27 So far,
only a single, tetramer-based study has analyzed the correlation of
spontaneously occurring circulating specific T cells in patients with
melanoma with survival, but it did not apply functional assays and
failed to report a prognostic impact.28
The aim of the present study was to investigate the prognostic
relevance of functional circulating T cells responding to the tumor-
associated antigens NY-ESO-1, Melan-A, MAGE-3, and survivin on
overall survival of patients with melanoma with distant metastasis.
PATIENTS AND METHODS
Patients
Cryopreservedperipheral bloodmononuclear cells (PBMCs)were accessed
from theDepartments of Dermatology, UniversityMedical Centers of Tu¨bingen
and Essen (Tu¨bingen and Essen, Germany), and the Department of Medical
Oncology and Immunotherapy, University Hospital of Siena, (Siena, Italy). Pe-
ripheral blood lymphocyteswere obtained from theNijmegenCentre forMolec-
ular Life Sciences (Nijmegen, the Netherlands). Additional fresh blood samples
were received from the Blood Bank andDepartment ofDermatology, University
MedicalCenterofTu¨bingen.PBMCswere immediately isolated fromfreshblood
by Ficoll-Hypaque density gradient centrifugation and cryopreserveduntil use.
Available biobanked samples from patients with melanoma who
fulfilled the following criteria were obtained from the clinical centers:
cohort A, patients with unresectable distantmetastases at the time of blood
draw and available follow-updata after blooddraw; cohort B, no radiologic
or clinical evidence of disease at blood draw,  24 months since first
diagnosis of distant metastasis, history of visceral metastasis other than
lung or elevated LDH (long-term survivors); cohort C, no history of
cancer. All patients provided written informed consent for biobanking.
This study was approved by the ethics committee in Tu¨bingen (approvals
147/2011BO2 and 432/2011BO2).
Detection of Antigen-Responsive T Cells
T-cell responses against NY-ESO-1,Melan-A,MAGE-3, and survivin
were measured as described previously.29 Briefly, cells were stimulated
with protein-spanning overlapping peptides (1 g/mL; PepMix; JPT Pep-
tide Technologies, Berlin, Germany). After culture for 12 days, T cells were
restimulated at a ratio of 1:2 with autologous, carboxyfluorescein succin-
imidyl ester (CFSE) –stained PBMCs (5 mol/L CFSE; Invitrogen,
Karlsruhe, Germany) either unpulsed (negative control) or presenting one
of the antigens in the presence of Golgi-Plug (1 L/mL; BD Biosciences,
Toronto, Ontario, Canada). After 12 hours of coincubation, Fc receptors
were blocked with Gamunex (human immunoglobulin; Bayer, Le-
Table 1. Patient Characteristics and Results of Survival Analysis Based on
Kaplan-Meier Method
Factor
Patients
1-Year Survival
Rate
P†No. % % Dead % 95% CI
Age, years .755
 55 41 48.8 73.2 35.8 20.9 to 50.7
 55 43 51.2 81.4 50.1 35.0 to 65.2
Sex .715
Male 56 66.7 75.0 40.1 27.0 to 53.2
Female 28 33.3 82.1 48.9 30.1 to 67.7
M category .024
M1a or b 22 26.5 68.2 58.7 37.9 to 79.5
M1c 61 73.5 82.0 36.3 24.0 to 48.6
NY-ESO-1–responsive T cells  .001
Present 36 42.9 61.1 63.3 47.4 to 79.2
Absent 48 57.1 89.6 27.5 14.6 to 40.4
Melan-A–responsive T cells .011
Present 22 31.9 63.6 59.1 38.5 to 79.7
Absent 47 68.1 83.0 37.2 23.1 to 51.3
Missing 15 80.0 37.5 12.0 to 63.0
MAGE-3–responsive T cells .042
Present 38 60.3 71.1 49.3 33.2 to 65.4
Absent 25 39.7 92.0 28.0 10.4 to 45.6
Missing 21 71.4 49.5 27.2 to 71.8
Survivin-responsive T cells .374
Present 8 15.1 62.5 58.3 21.8 to 94.8
Absent 45 84.9 80.0 34.4 20.3 to 48.5
Missing 31 77.4 51.6 34.0 to 69.2
Prior systemic treatments
Anti-CTLA4 .218
Yes 9 10.7 44.4 64.8 32.5 to 97.1
No 75 89.3 81.3 40.2 28.8 to 51.6
Other immunotherapy .260
Yes 39 46.4 74.4 49.7 33.6 to 65.8
No 45 53.6 80.0 37.6 23.5 to 51.7
Monochemotherapy .505
Yes 22 26.2 72.7 36.2 14.4 to 58.0
No 62 73.8 79.0 45.1 32.8 to 57.4
Polychemotherapy .802
Yes 7 8.3 71.4 35.7 74.5 to 74.5
No 77 91.7 77.9 43.5 32.3 to 54.7
Biochemotherapy .447
Yes 7 8.3 57.1 53.6 14.2 to 93.0
No 77 91.7 79.2 42.0 30.8 to 53.2
Subsequent systemic
treatments
Anti-CTLA4 .421
Yes 18 21.4 61.1 54.5 31.2 to 77.8
No 66 78.6 81.8 39.9 27.9 to 51.9
Other immunotherapy .656
Yes 17 20.2 88.2 47.1 23.4 to 70.8
No 67 79.8 74.6 42.0 30.0 to 54.0
Monochemotherapy .171
Yes 36 42.9 86.1 37.6 21.5 to 53.7
No 48 57.1 70.8 47.0 32.7 to 61.3
Polychemotherapy .164
Yes 19 22.6 89.5 35.1 13.0 to 57.2
No 65 77.4 73.8 45.4 33.2 to 57.6
Biochemotherapy .713
Yes 12 14.3 91.7 66.7 40.0 to 93.4
No 72 85.7 75.0 39.0 27.4 to 50.6
Two- and 3-year survival rates provided in Appendix Table A1, online only.
†P values are results of log-rank tests, excluding patient cases with missing values.
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verkusen, Germany), and dead cells were labeled with ethidium monoa-
zide (Invitrogen, Karlsruhe, Germany). Cells were fixed and permeabilized
with CytoFix/CytoPerm (BD Biosciences) and stained with the following
antibodies: CD3/Qdot655 and anti-CD4/Pacific Orange (Invitrogen);
CD8/APC-H7, IL-4/APC, and IFN-/PE-Cy7 (BD Biosciences); TNF/PE
(Miltenyi Biotec, Bergisch Gladbach, Germany); IL-10/Pacific Blue and IL-
17/PerCP-Cy5.5 (eBioscience, San Diego, CA); and IL-2/Alexa700 (BioLeg-
end, San Diego, CA). Samples were measured immediately using LSR II and
FACSDiva software (BD Biosciences). Data were analyzed using FlowJo soft-
ware (TreeStar, Ashland, OR). After removal of the duplicates using the
forward-scatter area versus forward-scatter height plot, autologous stimulator
cells were excluded by gating on the CFSE-negative cells. Next, CD4 and
CD8 cells were gated within viable CD3 lymphocytes and analyzed sepa-
rately for the production of cytokines. For each cytokine, we evaluated the
percentage of cytokine-producing cells among all gated T cells in sample one
(restimulated with antigen-pulsed PBMCs) and sample two (restimulated
with unpulsed PBMCs). For each cytokine, antigen-responsive T cells were
defined as present if the stimulation index was  2 (sample one divided by
sample two) and a clearly separate cytokine-producing population distin-
guishable fromthenonproducing cellswaspresent in sampleone, as described
previously.30 The patient was defined as having antigen-responsive T cells for
the analyzed cytokine if these criteria were met either for CD8 or CD4 T
cells. The interpretation of fluorescence-activated cell sorting data and the
response evaluation were performed according to established criteria for in-
tracellular cytokine staining, as described previously.29 All experiments were
performed and analyzed centrally by one investigator (H.Z.). To ensure the
quality of samples and the functional capacity of T cells, the cytokine response
after stimulation by influenza matrix protein 1 and nucleocapsid protein (1
g/mL; PepMix; JPT Peptide Technologies) was assessed as for the tumor-
associated antigens. Only patients with detectable influenza-responsive T cells
were further analyzed. Assay reproducibility was assessed in 61 additional
independent experiments performed exclusively in patients participating in
this study. The initial result (detection of antigen-responsive T cells, yes or no)
was confirmed in 51 of these assays (84%).
Statistics
The presence of antigen-responsive T cells was analyzed separately for
NY-ESO-1, MAGE-3, Melan-A, and survivin. Additional prognostic factors
consideredwere age (dichotomized using themedian of the distribution), sex,
AJCCM category (M1a or b vM1c), and systemic treatments applied before
and after blood draw. Therapies were aligned to the following categories:
treatment with anti-CTLA4 antibody, immunotherapy other than anti-
CTLA4 antibody, monochemotherapy, polychemotherapy, and biochemo-
therapy. Follow-up timewas defined from the datewhen bloodwas drawn for
T-cell analysis to the date of last follow-up or death. Disease-specific survival
probabilities were calculated, and only deaths resulting frommelanoma were
considered, whereas deaths resulting from other causes were regarded as
censored events. Estimates of cumulative survival probabilities according to
the Kaplan-Meier method were described together with 95% CIs and com-
pared using log-rank tests.Median survival times (MSTs) are presented.Mul-
tivariable Cox proportional hazards analyses were used to determine the
independent effect of prognostic factors. All variables were considered in
multivariable analysis. In the first model (model A), patients with missing
values of significant factors were excluded. In the second model (model B),
missing values were dummy coded to allow the inclusion of all patients. Both
models were established using backward and forward stepwise procedures.
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Fig 1. Survival of patients with unresectable stage IV disease according to the presence or absence of T cells responding to (A) NY-ESO-1, (B) Melan-A, (C) MAGE-3,
and (D) survivin peptides.
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Remaining nonsignificant factors were assessed for potential confounding
effects. Changes in the estimates of factors in a model by more than 5% were
regarded as indicative for confounding. Results of the Cox model were de-
scribed by means of hazard ratios (HRs) together with 95%CIs, and P values
were based on the Wald test. Throughout the analysis, P values .05 were
considered statistically significant. All analyses were carried out using SPSS
version 19 (SPSS, Chicago, IL).
RESULTS
Patients
PBMCs initially collected for biobanking purposes were requested
bytheparticipatingclinicalcentersaccordingtotheinclusioncriteria.One
of 117 samples was excluded from further analysis because influenza-
responsivefunctionalTcellscouldnotbedetected.Theother116patients
were assigned to three cohorts: 84 patients with unresectable distantme-
tastasis and clinical follow-up after T-cell analysis (cohort A), 18 tumor-
freelong-termsurvivors(cohortB),and14healthycontrols(cohortC).In
cohortA(67%male), theMSTwas9.7months.Medianfollow-upwas24
monthsfor19patientswhowerealiveatthelastfollow-upand6.5months
for 65 patients who died; 73.5% of patients were assigned to theM cate-
goryM1c.Median agewas 55 years, with an interquartile range (IQR) of
45 to 67 years. The 18 tumor-free long-term survivors of cohort B (also
67%male) had amedian age of 56.5 years (IQR, 48 to 68 years).Healthy
controlshadamedianageof45years(IQR,41to59years),and50%were
men(cohortC).NopatienthadreceivedNY-ESO-1orMelan-Avaccines
before blooddraw forT-cell analysis.
T-Cell Analysis Correlates With Overall Survival
In univariate analysis of 84 cohort A patients, the presence of T
cells responding to eitherNY-ESO-1,Melan-A, orMAGE-3was asso-
ciated with improved overall survival (Table 1; Fig 1; Appendix Table
A1, online only). The most significant difference in survival for patients
with responsive T cells versus those without was seen for NY-ESO-1
(P .001), with Melan-A less significant at P .011 and MAGE-3 at
P  .042, whereas the presence or absence of T cells responsive to
survivin peptides was not associatedwith survival in this analysis. The
MST of patients possessing T cells responding to NY-ESO-1 and/or
Melan-A was 21months, compared with 6months for all others (Fig
2A). The survival benefit was also evident when the analysis was
limited to thedetectionof IFN-–producingTcells (Fig2B)andwhen
CD4 andCD8T cells were analyzed separately (Appendix Fig A1,
online only). The individual frequencies of IFN-–producing cells
after stimulation with NY-ESO-1 andMelan-A for cohort A patients
are listed in Appendix Table A2 (online only). As expected, the M
category (Table 1) was also prognostic: the MST was 21 months for
patientswith soft tissue or lungmetastases andnormal LDH(M1a/b),
whereas it was 8 months for those with other visceral metastases or
elevated LDH (M1c; P .024). Multivariable Cox proportional haz-
ards analysis of 53patientswith completedataonall significant factors
(model A) showed that the presence of T cells targeting NY-ESO-1
(HR, 0.29; P .001) orMelan-A (HR, 0.18; P .001) were indepen-
dently associated with a survival benefit, whereas for the M category
andTcells responding toMAGE-3,noadditional significantprognos-
tic impact was found (Table 2).Model B included patients withmiss-
ing data. In agreement with model A, this analysis of 83 patients
confirmed the prognostic impact of NY-ESO-1– and Melan-A–
responsive T cells, whereas significant independent roles of the M
category and MAGE-3 were likewise not observed (Table 3). A com-
plete analysis of T-cell responses against all four antigens was per-
formed in 44 patients. There was a strong correlation between the
numberof targetedantigens and survival. Patientswithno response to
any antigen, a response to a single antigen, or responses to at least two of
the fourantigenshadanMSTof4, 6, or24months, respectively (Fig2C).
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Fig 2. (A) Patients with circulating T cells responding to Melan-A and/or
NY-ESO-1 by producing at least one of six cytokines have a median survival time
of 21 months, compared with 6 months for those who are negative for both. (B)
Impact of Melan-A– and/or NY-ESO-1–responding interferon-–positive T cells on
survival. (C) Survival according to the number of targeted antigens per patient.
Only patients with analysis of responses to all four antigens are considered.
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Noassociationbetweensurvival and the frequency of influenza-specific
IFN-–producingCD4/CD8Tcellswasobserved (datanot shown).
Antigen-Responsive T Cells in Long-Term Survivors
T cells responding to NY-ESO-1 and Melan-A peptides were
detectable in 50% and 47%, respectively, of long-term survivors in
cohort B. Such T cells were also found in a high proportion of cohort
A patients who survived 18months after analysis. In contrast, only
22%or 23%of patientswhodiedwithin 6months afterT-cell analysis
possessed detectable peripheral blood NY-ESO-1– or Melan-A–
specificTcells, respectively.Thiswas similar to thebackground level in
healthy controls. MAGE-3–specific T cells were detectable in a high
proportionofhealthy controls (cohortC)butwere equally frequent in
patients of cohort A with the worst prognosis. Survivin-responsive T
cellswere rare andwere found inonly14%of long-termsurvivors (Fig
3). Five recurrences but no deaths were observed among 18 cohort B
patients after a median follow-up of 18 months. Interestingly, NY-
ESO-1–responsive T cells were detected in only one (20%) of five
patients who experienced relapse, in contrast to eight (62%) of 13
long-term survivors without recurrences thus far. Similarly, only one
(25%) of four long-term survivors who experienced relapse versus
seven (54%) of 13 long-term survivors who did not assessed for
Melan-A had responsive T cells. Appendix Tables A3 and A4 (online
only) list frequencies of antigen-responsive CD4 and CD8 T cells
according to cytokine response to antigen stimulation.
DISCUSSION
Functional circulating tumor antigen–reactive T cells were found to
have an important impact on survival of patients with advancedmel-
anoma in this study. Melan-A– and NY-ESO-1–reactive T cells con-
tributed independently to prognosis and predicted survival better
than the AJCCM category in patients with distant metastasis. More-
over, patients possessingT cells reactive tomore than one antigen had
better survival than those with T cells reactive to fewer. This finding
further supports but does not prove the hypothesis that antigen-
specificTcellsplayacausative role in thecontrolof tumorcells.Toour
knowledge, this is thefirst report to associate spontaneously occurring
functionalT-cell responses to survival inpatientswithmelanoma.The
proportion of patients with an NY-ESO-1– or Melan-A–stimulated
T-cell response was likewise high in the cohort of tumor-free long-
term survivors, indicating a prognostic value independent of tumor
burden. MAGE-3–reactive T cells were frequently found in healthy
controls, and the proportion was lower in all analyzed melanoma
cohorts, suggesting a disease-related decrease of responsiveness to this
antigen.TheMcategorywasstronglyassociatedwithprognosisaccording
tounivariate analysis but didnot remain independently significantwhen
Table 2. Final Model A of Multivariable Cox Proportional Hazards Analysis
Factor
Patients
HR 95% CI PNo. %
%
Dead
M category .943
M1a or b 18 34.0 77.8 0.97 0.48 to 2.00
M1c 35 66.0 77.1 1
NY-ESO-1–responsive T cells .001
Present 23 43.4 60.9 0.29 0.14 to 0.61
Absent 30 56.6 90.0 1
Melan-A–responsive T cells < .001
Present 16 31.9 56.3 0.18 0.08 to 0.42
Absent 37 68.1 86.5 1
MAGE-3–responsive T cells .341
Present 33 62.3 69.7 0.73 0.39 to 1.39
Absent 20 37.7 90.0 1
NOTE. Bold font indicates statistical significance.
Abbreviation: HR, hazard ratio.
Model A included 53 patient cases (those with missing values were
excluded) and was adjusted for confounding effects of M category, presence
of MAGE-3–responsive T cells and anti-CTLA4 treatment after T-cell analysis.
Table 3. Final Model B of Multivariable Cox Proportional Hazards Analysis
Factor
Patients
HR 95% CI PNo. %
%
Dead
M category .064
M1a or b 22 26.5 68.2 0.56 0.31 to 1.04
M1c 61 73.5 82.0 1
NY-ESO-1–responsive T cells .002
Present 35 42.2 62.9 0.42 0.24 to 0.73
Absent 48 57.8 89.6 1
Melan-A–responsive T cells .002
Present 22 32.4 63.6 0.36 0.19 to 0.69
Absent 46 67.6 84.8 1
MAGE-3–responsive T cells .103
Present 37 59.7 73.0 0.62 0.35 to 1.10
Absent 25 40.3 92.0 1
NOTE. Bold font indicates statistical significance
Abbreviation: HR, hazard ratio.
Model B included 83 patient cases (one had missing information for M
category and was excluded; those with missing values were assigned their
own category per characteristic; missing value categories for Melan-A–
specific T cells n  15 and MAGE-3 specific T cells n  21 were included)
and was adjusted for confounding effects of M category and presence of
MAGE-3–responsive T cells.
Tumor-free M1c analyzed after > 24 months survival in stage IV (n = 18)
Patients with unresectable stage IV who survived > 18 months after analysis (n = 23)
Patients with unresectable stage IV who survived 6-18 months after analysis (n = 25)
Patients with unresectable stage IV who survived < 6 months after analysis (n = 27)
Healthy controls (n = 14)
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Fig 3. Proportion of patients with T cells responding to NY-ESO-1, Melan-A,
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disease with follow-up after T-cell assay, and healthy controls.
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tested inconjunctionwithNY-ESO-1–andMelan-A–responsiveT cells
in anymodel of themultivariate analysis. Nevertheless, a strong trend
was foundaccording tomodelB (P .064),whereasmodelAnegated
any independent impact of the M category on survival. These differ-
encesmight have been caused by the small sample size and need to be
clarified in larger patient cohorts.
Biobanking efforts of different centers enabled us to include
samples from patients for whom clinical follow-up was already avail-
able. Antigen-reactive T cells, either occurring spontaneously or after
vaccination, have been investigated before, but their correlation with
survival remains inconclusive, andmost studies have not assessed any
aspects of the actual functional integrity of the T cells.21,22,26,28,31
Previousanalyseshave focusedondifferent tumor-associatedantigens
and methods to analyze T cell status. Van Oijen et al28 used tetramer
staining to analyze spontaneously occurringT cells in 62 patientswith
distantmetastasis. SpecificTcellsweredetected in68%ofpatients,but
no correlation of any of these cells with survival was observed. It has
beenreported that themajorityof tumorantigen–specificTcells in the
blood of patients withmelanoma are not able to lyse tumor cells or to
produce any cytokines.26 In contrast, here we analyzed functional
response bymeasuring cytokine productionon antigenic stimulation.
To minimize the risk of underestimating the frequency of T cells in
principle capable of responding tomelanoma-associated antigens, we
quantified production of six cytokines. Because of different and par-
tially opposing functions of these cytokines in adaptive immunity, we
also compared survival of cohortApatients basedonlyondetectionof
IFN-–releasing T cells, which confirmed the strong impact of these
functional T cells on survival. The frequency of tumor antigen–
reactivememoryTcells invivo is too lowtobedetecteddirectly exvivo
by intracellular cytokine staining. Therefore, we initially applied a
limited 12-day in vitro stimulation to ensure expansion of memory
and not naive T cells to a measurable extent. For stimulation, nested
overlapping 15-mer peptides, spanning entire protein antigens, were
used as stimuli, allowing us to include patients of any HLA type.
Furthermore, considering the increasing appreciation of the impor-
tance of T helper responses for tumor rejection over the last few
years,32,33 it is noteworthy that bothCD8 aswell as CD4 responses are
stimulated and analyzed simultaneously with this approach.34
The prognostic impact of spontaneously occurringmemory T cells
responsive toNY-ESO-1andMelan-Awasnot restricted topatientswith
limitedstageIVdisease;73.5%ofcohortApatientspresentedwithvisceral
metastases other than lung and/or elevated LDH. The analysis of their
T-cell responsesenabledustoidentifypatientswithachanceof long-term
survival, even among those in theM1c category.
Ourworkprovides a rationale for refining vaccination andT-cell
transfer strategies by targetingMelan-A andNY-ESO-1. Poor clinical
responses in previous trials might be explained by tumor-induced
escapemechanisms likedownregulationofHLAclass I or recruitment
of regulatory T cells tometastatic sites. For upcoming specific immu-
notherapies, combinations with newly available agents targeting im-
mune escapemechanisms should therefore be considered.
This analysis might also serve as a rationale for investigating the
pretherapeutic detection of circulating T cells reactive to melanoma-
associated antigens as a predictive marker for outcome after ipili-
mumab.8 Although the mode of action of this agent is incompletely
understood, it breaks tolerance by blocking CTLA-4 and amplifies
preexistentmemory immune responses,whichmightbedetectable by
our assay.Recent data implicate an associationbetweenoutcomeafter
ipilimumab treatment and the existence of post-treatment T-cell re-
sponses targeting NY-ESO-1.35,36
In conclusion, circulating functional T cells targeting melanoma-
associated antigens in patients with melanoma with distant metastasis
have strong prognostic impact. T cells responding to Melan-A peptides
(HR, 0.18; P .001) or NY-ESO-1 peptides (HR, 0.29; P .001) were
independently associated with a survival benefit and superior to the M
category in predicting outcome according to Cox regression analysis. In
addition, our findings provide a rationale for pursuing vaccination and
T-cell transfer strategies targetingMelan-A andNY-ESO-1.
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GLOSSARY TERMS
AJCC/UICC-TNMstaging: The TNMClassification ofMa-
lignantTumours (TNM) is a cancer staging system that describes the
extent of cancer in a patient’s body. Tdescribes the size of the tumor and
whether it has invadednearby tissue;Ndescribes regional lymphnodes
that are involved;Mdescribes distantmetastasis (spread of cancer from
onebodypart to another). TNMis developed andmaintained by the
InternationalUnionAgainstCancer (UICC) to achieve consensus on
one globally recognized standard for classifying the extent of spread of
cancer. TheTNMclassification is also used by theAmerican JointCom-
mittee onCancer (AJCC). In 1987, theUICCandAJCC staging systems
were unified into a single staging system. Prognosis of a patient is de-
finedby theTNMclassification.
Coxregressionanalysis:TheCoxproportional hazards regres-
sionmodel is a statisticalmodel for regression analysis of censored sur-
vival data. It examines the relationship of censored survival distribution
to one ormore covariates. It produces a baseline survival curve, covari-
ate coefficient estimateswith their standard errors, risk ratios, 95%CIs,
and significance levels.
MAGE-3: Protein encoded by the MAGE A locus.MAGE
genes are normally silent in normal tissues but expressed in
several cancers.
Melan-A: A melanoma-related antigen. MART-1 is absent in
all normal cells except for melanocytes and the retina. In addition, apart
from melanomas, MART-1 has not been observed in any other cancers.
Consequently, the MART-1 antigen is considered to have a melanoctye
lineage.
NY-ESO-1: Also known as CTAG1B or cancer/testis antigen 1B, the
gene codes for antigens recognized on neoplastically transformed
T cells.
Survivin: IAPs suppress host cell death in response to viral infection.
By binding to caspases, they directly inhibit apoptosis. Survivin and
xIAP are members of this family, differing perhaps in binding to selec-
tive caspases. BIRC5: Tumor-associated protein belonging to the group
of shared overexpressed antigens.
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